A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2061230110

Enrollment

1150

Registered

2024-03-14

Start date

2024-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

Tiragolumab: Tiragolumab will be administered IV Atezolizumab: Atezolizumab will be administered IV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eastern Cooperative Oncology Group performance status of 0 or 1 Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology Participants must have had complete resection of NSCLC Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy Participants must have recovered adequately from surgery and from adjuvant chemotherapy Tumor cell PD-L1 expression at >/= 1% Adequate hematologic and end-organ function

Exclusion criteria

Exclusion criteria: Any history of prior NSCLC within the last 5 years Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy NSCLC known to have mutation in the EGFR gene or an ALK fusion oncogene

Design outcomes

Primary

Measure	Time frame
efficacy Observation/Inspection	—

Secondary

Measure	Time frame
safety, efficacy, phamacokinetics Observation/Inspection	—

Countries

Argentina, Australia, Belgium, Brazil, China, France, Greece, Hong Kong, Italy, Japan, Mexico, Peru, Poland, Republic of Korea, Romania, Slovakia, Spain, Taiwan, Thailand, Turkey, United States

Contacts

Public ContactClinical trials information

Chugai Pharmaceutical Co., Ltd.

clinical-trials@chugai-pharm.co.jp+81-120189706

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026